secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGILE THERAPEUTICS INC (—)
CIK:        0001261249
Form:       8-K
Filed at:   2024-08-26T23:59:59+00:00
Accession:  0001104659-24-092914
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 5.07, 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agile Therapeutics acquired by Insud Pharma for $1.52/share, total enterprise value ~$45M
--------------------------------------------------------------------------------

- Shareholders approved merger on Aug 22, 2024; deal closed Aug 26, 2024.
- Each Agile share converted to $1.52 cash; total enterprise value ~$45M.
- Agile common stock to cease trading on OTCQB; company becomes indirect subsidiary of Insud.
- All directors and officers resigned; new board chaired by Salustiano Pérez, Robert Spina as CEO.
- Outstanding equity awards cancelled; RSUs converted to cash at same $1.52 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1261249/000110465924092914/0001104659-24-092914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1261249/000110465924092914/tm2422458d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-092914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer